1 / 1

Supplemental Fig. 2

Supplemental Fig. 2. a. 32Dp210. 32DP210. f. 32Dp210. g. 32Dp210. WP1193 ( m M) C 0.5 1.0 2.0 3.0 4.0. e. 32DP210. c. d. K562-R. C 15 30 45 60 (min).

joelle
Download Presentation

Supplemental Fig. 2

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Supplemental Fig. 2 a. 32Dp210 32DP210 f. 32Dp210 g. 32Dp210 WP1193 (mM) C 0.5 1.0 2.0 3.0 4.0 e. 32DP210 c. d. K562-R C 15 30 45 60 (min) WP1193 (M) WP1193 (M) Untreated 5 10 Imatinib (M) C 2.5 5.0 10 pTyr 360 Bcr-Abl pTyr177 Bcr-Abl C 30 60 90 (min) C 30 60 90 120 (min) C 30 60 90 120 (min) (WB) Anti-pTyr Ab4G10 WP1193 (10M) b. 32Dp210 P32 pBcr-Abl pTyr177 Bcr-Abl pBcr-Abl Bcr-Abl kinase pSTAT5 (Tyr694) WB (6h ) WB (WB) Grb2 WP1193 (10M) pTyr177 Bcr-Abl pGab2 Bcr-Abl WP1193 (M) Untreated 1 2.5 5 WP1193 (10 M)  - Actin (Sup)  - Actin  - Actin 32P pJak2 (WB) Gab2 (WB) anti- Abl Bcr-Abl b-Actin anti-Abl GRB2 Image Quant (%) 100 55 41 20 (WB)  - Actin Jak2 IP: Jak2 h.

More Related